VanEck Pharmaceutical ETF (PPH)

NASDAQ: PPH · IEX Real-Time Price · USD
+0.21 (0.27%)
At close: Dec 1, 2023, 4:00 PM
-1.55 (-1.97%)
After-hours: Dec 1, 2023, 7:47 PM EST
Assets $383.65M
Expense Ratio 0.36%
PE Ratio 19.02
Shares Out n/a
Dividend (ttm) $1.63
Dividend Yield 2.07%
Ex-Dividend Date Oct 2, 2023
Payout Ratio 39.46%
1-Year Return +1.08%
Volume 49,166
Open 78.35
Previous Close 78.51
Day's Range 78.35 - 78.87
52-Week Low 73.40
52-Week High 83.35
Beta n/a
Holdings 26
Inception Date Feb 1, 2000

About PPH

Fund Home Page

The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is issued by VanEck.

Asset Class Equity
Category Health
Region North America
Stock Exchange NASDAQ
Ticker Symbol PPH
ETF Provider VanEck
Index Tracked MVIS US Listed Pharmaceutical 25

Top 10 Holdings

56.80% of assets
Name Symbol Weight
Eli Lilly and Company LLY 8.43%
Novo Nordisk A/S NVO 6.61%
Johnson & Johnson JNJ 6.14%
Cencora COR 5.36%
McKesson Corporation MCK 5.27%
Novartis AG ADR NVSN.MX 5.12%
Haleon plc HLN 5.02%
AbbVie Inc. ABBV 5.00%
AstraZeneca PLC AZN 4.93%
Merck & Co., Inc. MRK 4.92%
View More Holdings


Ex-Dividend Amount Pay Date
Oct 2, 2023 $0.3398 Oct 6, 2023
Jul 3, 2023 $0.3891 Jul 7, 2023
Apr 3, 2023 $0.6641 Apr 10, 2023
Dec 28, 2022 $0.240 Dec 30, 2022
Oct 3, 2022 $0.2696 Oct 7, 2022
Jul 1, 2022 $0.2496 Jul 8, 2022
Full Dividend History


Pharma Is Out of Favor. 5 Drug Stocks With Room to Grow.

Despite Eli Lilly's monster 66.8% gain on the year because of weight-loss drugs, the S&P 500 Pharmaceuticals index is down 2.3%.

Other symbols: BMYJNJLLYPFE
18 days ago - Barrons

Biotech Stocks Are Rallying, but the Outlook Isn't Good

The XBI has been climbing this month. On Tuesday it jumped 5.4% to close at $70.91.

Other symbols: XBIXLV
18 days ago - Barrons

Disruptive Tech Theme of the Week: Weight Loss Revolution

According to the latest CDC National Diabetes Statistics Report, more than 37 million people have diabetes in the U.S., or 11.3% of the population. The statistics for obesity are also dismal, as the W...

5 weeks ago - ETF Trends

Weight Loss Drugs Could Prove Potent for PPH

Ozempic commercials are, at this point, ubiquitous and while that's an anecdotal example, it also represents confirmation that obesity drugs are the next big thing in the pharmaceuticals industry.

2 months ago - ETF Trends

How the Pharmaceutical Industry Is Using AI

Industry-leading pharmaceutical firms are adopting artificial intelligence (AI) to drive value for the future of their enterprise. AI is currently being implemented within the industry to reduce human...

7 months ago - ETF Trends

Growth, Innovation Could Fuel Pharma ETF Rebound

For much of 2020 and 2021, the pharmaceutical stock investment thesis revolved around development and disbursement of coronavirus vaccines. While that made for an obvious catalyst, and a rewarding one...

1 year ago - ETF Trends

3 ETFs for the Healthcare Sector's Highs

Investors looking for equities suddenly have more than a few options to consider in this mini-market rally. Whether markets have really priced in Fed action or a possible recession already or not, inv...

Other symbols: IHFPJP
1 year ago - ETF Trends

This ETF Is Home to Some of the Top Healthcare Stocks

The healthcare sector isn't setting the investment world ablaze this year, but it is outperforming the broader market, underscoring its defense posture.

1 year ago - ETF Trends

Pharma Stocks, ETFs Can Deal With Drug Pricing Legislation

This is a mid-term election year, meaning that some familiar issues investors should be aware of are popping up yet again. That includes reducing pharmaceutical prices.

1 year ago - ETF Trends

Pharmaceuticals Stocks, ETFs Could Have Power Beyond 2022

Pharmaceuticals stocks and the related exchange traded funds are benefiting from the now-steady revenue stream provided by coronavirus vaccines, but with that priced into many pharmaceuticals equities...

1 year ago - ETF Trends

Pharma Could Be Place to Be for Healthcare Winners, Value

Broadly speaking, the healthcare sector delivered some decent though not spectacular performances last year, with diversified exchange traded funds addressing the sector hindered by rough showings by ...

2 years ago - ETF Trends

Pharma Could Be Fabulous in 2022

Pharmaceuticals stocks and the related exchange traded funds are turning solid performances in 2021. Investors looking for quality and growth traits might want to continue leaning on this corner of th...

2 years ago - ETF Trends

Write a Prescription for Pharma Dividends With PPH

Domestic dividend growth is on a torrid pace this year, and market observers expect that the trend will continue in 2022. Investors searching for sector and industry exchange traded funds with which t...

2 years ago - ETF Trends

Omicron Variant Could Be Potent for Pharma Stocks, ETFs

According to reports out Wednesday, the first U.S case of the Omicron variant of the coronavirus was discovered in California. More research is needed on the Omicron strain, but there's already ample ...

2 years ago - ETF Trends

There's Power Lurking in This Pharma ETF

Blue-chip pharmaceuticals stocks are turning solid showings this year, but the group is lagging the broader market, indicating that some of the coronavirus vaccine blush is wearing off the group. Howe...

2 years ago - ETF Trends

PPH Pertinent as Some Cheap Pharma Stocks Offer Big Dividend Growth

Healthcare stocks are solid but not spectacular performers. For example, the S&P 500 Health Care Index is higher by more than 17%, though that lags the broader market.

2 years ago - ETF Trends

Strong Vaccine Demand Lifting Pharma Sales

There are multiple coronavirus vaccines on the market, and with the likelihood of booster shots increasing by the day, the revenue outlook for healthcare exchange traded funds, including the VanEck Ve...

2 years ago - ETF Trends

Alzheimer's Drug Cost Pushes Pharmaceutical Prices Back Into the Spotlight

Biogen's (NASDAQ: BIIB) Aduhelm sparked a rally in the biotech giant's share price and hope that progress is being made in treating Alzheimer's. However, the news isn't free of controversy, and carrie...

2 years ago - ETF Trends

Artificial Intelligence Set to Transform the Pharmaceutical Industry

The pharmaceuticals industry got a boost last year when a Covid-19 vaccine was introduced, but artificial intelligence (AI) could keep the sector and ETFs like the VanEck Vectors Pharmaceutical ETF (P...

2 years ago - ETF Trends

Pharma Goes Beyond the Vaccine. ‘PPH' on the Verge of More Advances

Coming off a vaccine rally that started in the middle of 2020, the pharmaceutical industry will continue to evolve as technological advances make their way into the sector, which should help ETFs like...

2 years ago - ETF Trends

Beyond the Vaccine: The Long Runway for Health and Pharmaceutical ETFs

With 2020 election season in the rearview mirror, it could be a great time to revisit health and pharmaceutical ETFs, including the VanEck Vectors Pharmaceutical ETF (NASDAQ: PPH). PPH tracks the MVIS...

3 years ago - ETF Trends

Write A Prescription For This Pharma ETF

After scuffling amid political uncertainty leading up to Election Day, pharmaceutical stocks and exchange-traded funds are finally perking amid a spate of encouraging news regarding coronavirus vaccin...

3 years ago - Benzinga

Pharma Sector Steps up as a Portfolio Prescription

By VanEck Hope Springs Eternal Hopes of a return to normality are increasing after a year of pandemic-induced tumult. News that COVID-19 vaccines developed by Pfizer and BioNTech, and Moderna were mor...

3 years ago - ETF Trends

Some Good Deals Are Available in Pharmaceuticals ETFs

Investors looking for compelling valuations don’t have to go deep into the lagging value factor. They can harness some growth with pharmaceuticals ETFs, including the VanEck Vectors Pharmaceutical ETF...

3 years ago - ETF Trends

A Divergence Has Occurred In Healthcare

For the first four months of the market’s cornavirus recovery, one of the key themes was the dominance of biotech.

Other symbols: BBH
3 years ago - Benzinga